Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by US Bancorp DE

US Bancorp DE boosted its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 62.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,616 shares of the company’s stock after buying an additional 11,810 shares during the period. US Bancorp DE’s holdings in Verve Therapeutics were worth $173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of Verve Therapeutics by 139.8% in the third quarter. Barclays PLC now owns 222,919 shares of the company’s stock valued at $1,079,000 after purchasing an additional 129,944 shares during the period. State Street Corp increased its holdings in shares of Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock valued at $20,586,000 after purchasing an additional 903,809 shares during the period. Braidwell LP acquired a new position in shares of Verve Therapeutics in the third quarter valued at about $3,020,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Verve Therapeutics by 28.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after purchasing an additional 126,110 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Verve Therapeutics by 465.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company’s stock valued at $241,000 after purchasing an additional 35,214 shares during the period. 97.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on VERV shares. HC Wainwright increased their price objective on Verve Therapeutics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, February 28th. Royal Bank of Canada dropped their target price on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Finally, William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Verve Therapeutics currently has an average rating of “Buy” and an average price target of $25.50.

Verve Therapeutics Stock Down 2.9 %

Verve Therapeutics stock opened at $5.97 on Friday. The firm has a market cap of $530.11 million, a price-to-earnings ratio of -2.43 and a beta of 1.77. Verve Therapeutics, Inc. has a 52 week low of $4.31 and a 52 week high of $14.26. The business’s 50-day moving average price is $6.98 and its 200 day moving average price is $6.10.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.